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A method for determining a safety range for non-cancer risks is proposed, similar in concept to the range
used for cancer in the management of waste sites. This safety range brings transparency to the chemical
speciﬁc Reference Dose or Concentration by replacing their “order of magnitude” deﬁnitions with a
scientiﬁcally-based range. EPA’s multiple RfCs for trichloroethylene (TCE) were evaluated as a case study.
For TCE, a multi-endpoint safety range was judged to be 3 mg/m3 to 30 mg/m,3 based on a review of
kidney effects found in NTP (1988), thymus effects found in Keil et al. (2009) and cardiac effects found in
the Johnson et al. (2003) study. This multi-endpoint safety range is derived from studies for which the
appropriate averaging time corresponds to different exposure durations, and, therefore, can be applied to
both long- and short-term exposures with appropriate consideration of exposure averaging times. For
shorter-term exposures, averaging time should be based on the time of cardiac development in humans
during fetal growth, an average of approximately 20e25 days.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Risk managers responsible for making choices about accept-
able oral and inhalation chemical exposures at hazardous wasteRisk Assessment (TERA) Cen-
Panzeca Way, Kettering Lab-
dagbui).
often managed using risk
S. Environmental Protection
ntrations such as Regional
ed concentrations (RBCs) or
ved using these EPA methods
idely used in the assessment
ental sources.
r Inc. This is an open access article usites1 have typically focused ﬁrst on concerns about cancer. As risk
managers became increasingly familiar with how to effectively
manage these cancer risks, it became routine to make screening
and closure decisions using the widely accepted 100-fold upper-
bound, excess, lifetime, cancer risk range of 104 to 106 (U.S.
Environmental Protection Agency (EPA), 1991a). This range
allowed managers the ﬂexibility needed to address the risk at
waste sites that differed with respect to environmental setting,
history, and current and future uses, based on the needs of the
community.
Risk managers have also always considered non-cancer health
effects in this process, but such effects often did not drive man-
agement decisions, or when they did, the evaluation lacked a cor-
responding non-cancer risk range. For example, risk managers
generally applied a Hazard Quotient (HQ) of 1 as the criterion for ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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values.2 The HQ concept is used by various agencies, each using its
allowable health protective level as the denominator in the equa-
tion (for examples of these levels please see: http://toxnet.nlm.nih.
gov/newtoxnet/iter.htm). Although EPA (Barnes and Dourson,
1988; EPA, 1994, 2002) and others such as Felter and Dourson
(1998) have shown that the information underlying the HQ, that
is, the Reference Dose (RfD) or Reference Concentration (RfC)
[collectively referred to here as the RfD(C)], possesses “uncertainty
spanning perhaps an order of magnitude,” risk managers have
generally not implemented decisions based upon this stated un-
certainty. Consequently, non-cancer hazards have frequently been
evaluated and regulated as if a bright line existed when exposures
were at, or very near, the RfD or RfC, i.e., where the hazard quotient
of one (1) or less was interpreted as without risk, and values greater
than 1 were associated with some unspeciﬁed, unacceptable risk.
It can be easily argued that the phrase in the deﬁnition of an
RfD(C) “with uncertainty spanning perhaps an order of magnitude”
is precautionary. This is because the RfD(C) derivation process
contains several uncertainties, and the application of a factor for
each of these uncertainties provides amargin of safety based on the
behavior of the “average” chemical (Dourson and Stara, 1983;
Dourson et al., 1996). Since most determinations of the RfD(C)
have more than one source of uncertainty, and consequently
exhibit multiple successive precautionary adjustments (i.e., the
application of multiple uncertainty factors), this implicit margin of
safety increases as the overall uncertainty factor gets larger, as does
the implicit protectiveness of the resulting RfD(C), as demonstrated
theoretically by Swartout et al. (1998).
Since their origin by Barnes and Dourson (1988) and EPA (1994),
RfDs and RfCs have increasingly been based upon more sophisti-
cated data, algorithms and models (e.g., Renwick, 1991, 1993;
Renwick and Walker, 1993; Jarabek, 1995a, 1995b; Dourson et al.,
1996; Guth et al., 1997; Kalberlah and Schneider, 1998; Meek
et al., 2001; Haber et al., 2001, 2002; Dourson and Younes, 2002;
EPA, 2002; Dourson and Patterson, 2003; IPCS, 2005; Seed et al.,
2005; Dourson and Parker, 2007; Gentry et al., 2003; EPA, 2012b;
Meek et al., 2014; Dourson et al., 2013). This increased sophisti-
cation has deﬁned internal concentrations from exposure dosing,
accounted for toxicokinetic differences between the test animal
and human populations, characterized route-to-route internal dose
extrapolations, and interpolated effects levels between the LOAEL
and NOAEL in the experimental study, among others. These
probability-based elements fundamentally change the RfD(C)
development process and necessitate a clearer understanding of
risk in practical application. These changes require the user to go
beyond the bright line decision process currently employed. Expert
bodies are also urging such movement (NAS, 2009, 2014; EPA,
2014). For example,
“EPA should clearly present two dose-response estimates: a
central estimate (such as a maximum likelihood estimate or a
posterior mean) and a lower-bound estimate for a POD from
which a toxicity value is derived. The lower bound becomes an
upper bound for a cancer slope factor but remains a lower
bound for a reference value.” And further on: “EPA should
develop IRIS-speciﬁc guidelines to frame uncertainty analysis
and uncertainty communication. Moreover, uncertainty analysis2 For ingestion exposures, the hazard quotient (HQ) is the ratio of an average
daily dose to the Reference Dose (RfD). For inhalation exposures, the HQ is the ratio
of the exposure concentration of a substance (EC) to its Reference Concentration
(RfC). The HQ associated with acceptable exposures is generally one (1), with a
precision of one signiﬁcant ﬁgure (i.e., an implicit HQ range of 0.95e1.5).should become an integral component of the IRIS process” (NAS,
2014; page 130).
In addition, risk managers must now contend with situations
where risk management decisions at sites may be driven by non-
cancer endpoints, even when the cancer endpoint has also been
quantitatively deﬁned for a given chemical. For example, the RfD
and RfC values for trichloroethylene (TCE) have been revised to
lower levels, suggesting greater toxicity than before (EPA, 2011),
whereas the available cancer risk-speciﬁc doses have increased
slightly, suggesting less cancer risk. Therefore, in any given expo-
sure setting, the resulting HQ for the non-cancer endpoints for TCE
is correspondingly increased (i.e., indicative of greater toxicity). As a
result, these lower RfD and RfC values are now within the 104 to
106 range of risk-speciﬁc doses or risk-speciﬁc concentrations
associated with the cancer endpoint. Consequently, risk managers
may encounter unfamiliar challenges in making effective risk
management decisions at sites with TCE contamination, in part
because the non-cancer endpoint does not have an associated risk
range.
These challenges to effective risk management are not simply
academic. For example, TCE exhibits signiﬁcant toxicity from both
oral and inhalation exposures, and is frequently encountered at
contaminated sites (ATSDR, 2015). Moreover, TCE has been re-
ported as part of “background” conditions in about half the resi-
dential structures in the United States (Dawson andMcAlary, 2009),
with higher background concentrations approaching the range of
EPA’s RfCs. For TCE speciﬁcally, risk managers are thus confronted
with twin challenges: (1) the discernment of TCE concentrations
that are attributable to environmental (subsurface) contamination
from TCE concentrations from those that are associated with con-
founding, background sources and (2) determining a remedial
objective resulting in acceptable indoor air concentrations of TCE.
The multiple variables affecting potential and actual human expo-
sures to TCE are relevant and important to risk managers, and these
variables amplify the need for a clearer understanding of the non-
cancer hazards associated with environmental concentrations
above the RfD or RfC, represented by HQ values greater than 1.
In part because of these concerns, the Alliance for Risk Assess-
ment (ARA) was petitioned to form a coalition to develop guidance
to facilitate effective risk management decisions at TCE-
contaminated sites. Several open meetings and deliberations
were held in 2012 and 2013; these efforts culminated in a guidance
document posted at http://allianceforrisk.org/guidance-for-
contaminated-sites/. The analysis presented herein is based in
part on this work. Speciﬁcally, this paper proposes a process to
determine a range that is consistent with the uncertainty in the RfD
or RfC, and that is similar in concept to the acceptable risk range of
106 to 104 for upper-bound, excess, lifetime, cancer effects. This
“safety range”would allowmanagers to have comparable ﬂexibility
in the management and/or regulatory closure of waste sites,
particularly where the evaluation of non-cancer effects drives the
risk assessment. The evaluation of the non-cancer effects associ-
ated with TCE is used as an example to illustrate the determination
of this safety range and its subsequent application in risk man-
agement due its prevalence at waste sites. The choice of TCE is
particularly relevant because of its overlapping exposure concen-
trations associated with its cancer and non-cancer effects, and the
uncertainties associated with its confounding background sources
resulting in exposure concentrations near the RfC.2. Methods
The information used to evaluate the TCE risk assessment values
4 For example, see Dourson and Stara (1983), which states, “A possible modiﬁ-
cation to the standard approach would be to present a range for the ADI rather than
one value. The range could be based at the high end on the average reductions in
dose needed to estimate the ADI (from Figs. I and 3) and the body-surface area ratio
(Fig. 2), and at the low end on the standard 10-fold reductions.” (p. 234). The ADI is
the acceptable daily intake, a parameter that is similar or equivalent to the RfD,
both of which are usually represented in units of milligram per kilogram body
weight per day (mg/kg-d). This recommendation is similar to that suggested by NAS
(2014, vide supra).
5 Please note that the use of the Johnson et al. (2003) study is for demonstration
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(IRIS) report (2011). EPA identiﬁed three candidate RfC values for
non-cancer inhalation toxicity. These three candidates are
described brieﬂy as:
 a candidate RfC of 3 mg/m3, based on toxic nephropathy in fe-
male rats (NTP, 1988);
 a candidate RfC of 2 mg/m3 based on decreased thymusweight in
female mice (Keil et al., 2009);
 a candidate RfC of 2 mg/m3 based on fetal heart malformations in
rats (Johnson et al., 2003); however, at least one letter to the
editor and 2 errata have been published clarifying errors in the
original report (Anonymous, 2005; Hardin et al., 2004; Johnson
et al., 2004); ﬁndings from ﬁve studies conducted from 1989 to
1995 (US EPA, 2011) using a novel dissection method, and have
not been conﬁrmed using guideline compliant, GLP methods.
Each of the candidate RfC values may be evaluated with respect
to its underlying uncertainty, including the precision and the safety
inherent in its derivation.
The safety range for each candidate RfCwas built from the actual
deﬁnition of the RfD(C) as having “uncertainty spanning perhaps an
order of magnitude.”We evaluated each of the candidate RfC values
with respect to its underlying uncertainty, including the precision
and the safety inherent in its development by focusing on the word
“perhaps” by Barnes and Dourson (1988). This wordwas used in the
deﬁnition because of the variation in the underlying toxicity da-
tabases of different chemicals (as per author Dourson). For
example, a chemical database may have sufﬁcient information in
humans and experimental animals so that the resulting RfD(C) can
be developed with a one-fold or three-fold uncertainty factor.
Uncertainty in such an RfD(C) is smaller, that is, perhaps less than an
order of magnitude. In other cases, fewer data are available so that
the resulting RfD(C) is developed with an aggregate uncertainty
factor of 1000 ormore. Uncertainty in these RfD(C) values is greater,
that is, perhaps more than an order of magnitude.
The uncertainty in each RfD(C) value includes its inherent pre-
cision and safety. Precision refers to the repeatability of the overall
process. What this means for a RfD(C) is how close a second RfD(C),
estimated for the same chemical given the same information,
would be if developed by a different expert or expert group. In such
cases, the precision might be best characterized as perhaps three-
fold on either side of the RfD(C) (Felter and Dourson, 1998; EPA,
2002), although this could be less than or greater than a three-
fold margin, as described above.
Within the uncertainty of each RfD(C), the concept of safety
refers to the determination of its degree of protectiveness. This
degree of protectiveness is expected to vary, because a RfD(C) is
developed using one or more uncertainty factors, each of which is
protective based on the observed behavior of the “average”
chemical (Dourson and Stara, 1983; Dourson et al., 1996). This
protectiveness provides assurance that any RfD(C) is an underes-
timate of the expected value of the actual safe dose, i.e., the No
Observed Adverse Effect Level (NOAEL) for a sensitive human
subpopulation.3 Furthermore, the use of multiple uncertainty fac-
tors results in even more protective RfD(C) values as theoretically
demonstrated by Swartout et al. (1998). Because of this, the portion
of the uncertainty in an RfD(C) associated with safety is best
characterized as a range above the RfD(C), where the latter is3 This follows directly from the deﬁnition of the RfD or RfC, and is reﬂected in
several examples on EPA’s Integrated Risk Information System (IRIS) where NOAEL
values for a sensitive human subpopulation have been used as the basis of an RfD
with an aggregate uncertainty factor of 1.considered as the ﬂoor to this safety range, i.e., the RfD(C) is the
lowest value within the range (Dourson and Stara, 1983; Felter and
Dourson, 1998).4
Based on this understanding of precision and safety within an
“order of magnitude,” we then developed a range associated with
each of the candidate RfCs for TCE. This rangewas developed with a
ﬂoor, a ceiling and an intermediate value, and because each of these
RfCs was based on different data, the ranges were anticipated to be
somewhat different. As further described in ARA (2013), criteria
chosen to reﬂect the judgment of this range included:
 overall conﬁdence in the RfC as demonstrated by the size of the
overall uncertainty factor;
 determination of the steepness of the dose response slope for
the speciﬁed effect (Summary from ARA. 2013);
 conﬁdence in the determination of the critical effect; and
 conﬁdence in the determination of the point of departure (POD).
Furthermore, since risk managers might wish to see an overall
safety range based on all three RfCs, we determined a “Multiple-
endpoint range of safety” through an integration of the above four
criteria for each of the three RfCs using professional judgment.
Finally, the overall safety rangewas compared to three hypothetical
TCE exposure scenarios to show how such a range might be used at
a waste site.3. Results
3.1. Deﬁning the uncertainty range in the TCE RfCs
As described in Methods, the precision of each of the candidate
RfCs may be considered as a uniform or equal distribution around
the RfC (i.e., the RfC is the central value of the distribution). This
precision would be expected to vary among the RfD or RfC values
for different chemical substances, and among the three different
candidate RfC values. This is because the individual and aggregate
uncertainty factors are unique to each risk value, and because the
judgment of the critical effect for a chemical substance is not al-
ways straightforward. Thus, a second expert groupmight develop a
different value given the same information.
TCE itself exempliﬁes this variation in precision. Depending on
the choice of critical effect and uncertainty factor, EPA (2011)
judged RfCs to be either 2 mg/m3 for the two candidate RfCs
based on either Keil et al. (2009) and Johnson et al. (2003),5 or to be
3 mg/m3 for the candidate RfC based on NTP (1988). The precision of
any one of these candidate RfC values can be determined by com-
parison to any second one. Depending on which TCE RfC is devel-
oped ﬁrst, this precision is either 30% lower or 50% higher.purposes only. During the course of this study, it became apparent that EPA’s use of
cardiac anomalies for developing an RfC is highly controversial and not universally
shared among government agencies and expert bodies (see supplemental mate-
rials, ARA, 2013, section 2). It may be that an analysis of this speciﬁc effect is
warranted by appropriate experts, but at the very least risk managers need to
understand that this endpoint cannot, by itself, be used with conﬁdence to form the
basis of any quantitative hazard estimate.
Table 1
Different safety ranges for candidate TCE RfCs. All values are in mg/m3. Shaded areas indicate best overall safety range for risk management purposes. See ARA (2013) for
additional discussion as described in supplemental materials.
Study IRIS UFa Steep Slopeb Conﬁdence Safety ranges
Critical Effectc Point of Departured Floor Intermediate Ceiling
Johnson et al. (2003) 10 Lower Low Low 2 10 20
NTP (1988) 10 Higher Medium Medium to Low 3 9 30
Keil et al., 2009 100 NA Medium Medium to Low 2 20 63
NA¼Not available.
a Size of the uncertainty factor as on IRIS.
b Steepness of the hazard slope (i.e., the slope of the line describing hypothetical population responses at concentrations above the RfC), as per ARA (2013)
c Conﬁdence in the choice of critical effect as per ARA (2013) and text.
d Conﬁdence in the point of departure as per ARA (2013) and text.
6 Our judgment of conﬁdence follows the EPA practice of deﬁning low conﬁdence
as the likelihood of new data changing the critical effect, point of departure, and/or
uncertainty factor (greater likelihood ¼ lower conﬁdence) (Dourson, personal
M.L. Dourson et al. / Regulatory Toxicology and Pharmacology 80 (2016) 125e133128In contrast to precision, the safety in each of the three candidate
RfC values for TCE is associated with a unique range of values that is
expected to lie above each candidate RfC, because choices made at
each step in the process of its derivation incorporate a margin of
safety. These choices include judgments of critical effects of
differing severity, the use of an effect that may not relate to
humans, the use of a lower limit on the benchmark dose (BMD),
and/or the use of a 10-fold default uncertainty factor in lieu of data
suggesting that a smaller uncertainty factor may be more appro-
priate. The range of safety may not be the same among these
candidate RfC values because each was developed using a different
critical effect, POD and aggregate uncertainty factor.
For risk management decisions, the range of safety associated
with each RfD or RfC is generally more important than the
respective range of precision. This is because risk managers are
interested in making decisions that are protective of public health
and it is an understanding of the range of safety in each RfD or RfC
that is generally more informative. With this risk management
mindset, we determined a unique safety range associatedwith each
candidate RfC for TCE as follows.
For each candidate RfC, the safety range is deﬁned by a ﬂoor
value based upon the actual candidate RfC point value, as described
on IRIS. This choice of the individual candidate RfC as the ﬂoor of
the range for each non-cancer endpoint is reasonable from a
practical point of view, because managers are unlikely to take
regulatory action at or below these values, due to the protective
nature implicit in the derivation of each candidate RfC, as described
above. However, using the RfD or RfC as the ﬂoor to a range in its
value also has theoretical support where it is shown that uncer-
tainty factors are protective based on the behavior of the average
chemical (see Methods). These ﬂoor values for each endpoint-
speciﬁc safety range are shown in Table 1.
For each candidate RfC, the safety range is also deﬁned by a
ceiling value based upon the POD for each candidate RfC, as
described on IRIS. This ceiling value is then further adjusted
downward, if needed, to reﬂect the known toxicokinetic differences
between the test organism and the human population in order to
determine the human equivalent concentration, and/or known
uncertainties in the overall database, such as the lack of NOAEL, a
study of insufﬁcient duration, or the lack of a study investigating
important endpoints. These reductions are based on available data,
or a default factor of three as per EPA (2002). The intent of these
reductions, if needed, is to estimate the likely human equivalent
NOAEL from a chronic experimental animal study (or other study
duration, if appropriate for the endpoint).
Speciﬁcally, the unadjusted ceiling value for each candidate
RfC’s safety range is the POD of 20 mg/m3 for cardiac effects from the
controversial Johnson et al. (2003) study, of 30 mg/m3 for kidney
effects from NTP (1988), and of 190 mg/m3 for immune effects from
the Keil et al. (2009). No adjustments were needed to the ﬁrst twoPODs because both of them represent the human equivalent NOAEL
for the duration of interest; however, an adjustment to the ﬁnal
POD from Keil et al. (2009) was considered necessary because it
was based on a LOAEL, rather than a NOAEL. The adjusted POD was
63 mg/m3 found by reducing the LOAEL of 190 mg/m3 by an uncer-
tainty factor of three. The use of three-fold uncertainty factor
represents the midpoint of the uncertainty factor of 10 for use of a
LOAEL. Each of these ceiling values is reasonable from a practical
point of view, because risk managers are likely to take regulatory
action at or above these values due to the fact that speciﬁc toxic
effects can sometimes be associated, or be anticipated, with them.
These ceiling values for each endpoint-speciﬁc safety range are also
shown in Table 1.
Because the range between the ﬂoor and ceiling varies for each
RfC, we also developed an intermediate value within each safety
range. This intermediate valuemight enable riskmanagers to gauge
whether to take regulatory action when exposures fall within the
range. The determination of the intermediate value of the safety
range for each RfD or RfC may encompass many attributes. As a
start, we mesh four considerations:
 size of the total uncertainty factor on EPA’s IRIS as a crude
measure of the overall uncertainty in the database;
 steepness of the hazard slope (i.e., the slope of the line
describing hypothetical population responses at concentrations
above the RfC, see supplemental materials, ARA, 2013, section
3);
 conﬁdence6 in the choices of critical effect; and
 conﬁdence in the POD.
The intermediate values of those safety ranges that are closer to
their respective candidate RfC (i.e., ﬂoor value) are generally asso-
ciated with a smaller aggregate uncertainty factor, a steeper hazard
slope, a higher conﬁdence in the critical effect, and a higher con-
ﬁdence in the POD. The intermediate values of those safety ranges
that are further from their respective RfC (i.e., ﬂoor value) are
generally associated with a larger aggregate uncertainty factor, a
shallower hazard slope, a lower conﬁdence in the critical effect, and
a lower conﬁdence in the POD.
For the controversial fetal malformation endpoint based on
Johnson et al. (2003), we judged the intermediate value of the
endpoint-speciﬁc uncertainty range to be 10 mg/m3, or ﬁve-fold
above its respective candidate RfC. This is due to its small aggre-
gate uncertainty factor of 10 (which argues for a value closer to the
candidate RfC), shallower hazard slope (which argues for a valueexperience as RfD(C) Work Group Co-Chair 1986 to 1994).
M.L. Dourson et al. / Regulatory Toxicology and Pharmacology 80 (2016) 125e133 129farther from the candidate RfC), low conﬁdence7 in the critical ef-
fect (which argues for a value farther from the candidate RfC), and
low conﬁdence in the choice of a benchmark response of 1% (which
argues for a value farther from the candidate RfC). See also sup-
plemental materials.
For the toxic nephropathy endpoint based on the NTP (1988)
study, we judged the intermediate value of the endpoint-speciﬁc
uncertainty range to be 9 mg/m3, or three-fold above its respec-
tive candidate RfC. This is due to its small aggregate uncertainty
factor of 10 (which argues for a value closer to the candidate RfC),
steeper hazard slope (which argues for a value closer to the
candidate RfC), medium conﬁdence in the critical effect (which
argues for a value neither closer to nor farther from the candidate
RfC), and medium to low conﬁdence in the choice of a benchmark
response of 5% (which argues for a value farther from the candidate
RfC). See also supplemental materials.
For the decreased thymus weight endpoint based on the Keil
et al. (2009) study, we judged the intermediate value of the
endpoint-speciﬁc uncertainty range to be 20 mg/m3, or 10-fold
above its respective candidate RfC due to its larger uncertainty
factor of 100 (which argues for a value farther from the candidate
RfC), medium conﬁdence in the critical effect (which argues for a
value neither closer to nor farther from the candidate RfC), and
medium to low conﬁdence in its choice of a lowest observed
adverse effect level (LOAEL) as the POD (which argues for a value
farther from the candidate RfC). The effect shown by Keil et al.
(2009) does not lend itself to dose response modeling, so a judg-
ment of steepness of hazard slope is not possible (see supplemental
materials.
The safety range for each candidate RfC is shown in Table 1.3.2. Deﬁning the multi-endpoint range of safety
Since EPA developed three candidate RfCs for non-cancer ef-
fects, the endpoint-speciﬁc safety range of each of the candidate
RfCs may be considered individually, or collectively, in risk man-
agement decisions. From the collective evaluation of the endpoint-
speciﬁc safety ranges of all three candidate RfCs, a “total safety
range” of 2 mg/m3 to 63 mg/m3may be inferred. However, extraction
of a “multi-endpoint safety range” from the broader total safety
range may be more useful for risk management decision-making.
The multi-endpoint safety range may be deﬁned here as an esti-
mate of “a daily exposure to the human population (including
sensitive subgroups) that is likely to be without an appreciable risk
of deleterious effects during a lifetime.” This is based upon the
deﬁnition of the RfD(C) (Barnes and Dourson, 1988; EPA, 1994,
2002), but where the phrase “with uncertainty spanning perhaps
an order of magnitude” is absent, because the range is now speci-
ﬁed for each RfD(C) value.
The POD for the RfD(C) is typically (although not always) based
upon a NOAEL from a single study for a single critical effect. The
assessment of conﬁdence levels in the study design, critical effect
and POD of a single study and critical effect enables the assignation
of uncertainty factors in a relatively straightforward manner. The
use of the deﬁnition of the RfD(C) to also deﬁne the multi-endpoint
safety range is a recognition of the complexity associated with the
prediction of a “safe dose” or “safe concentration” associated with
multiple effects, observed in multiple studies and species, and
multiple PODs, each variously based on a BMDL01, BMDL05 or LOAEL
value, appropriately averaged over two different exposure periods,7 Low conﬁdence argues for an intermediate value that is farther from the RfC
because choices of critical effect and POD in such situations are generally more
protective.as relevant for developmental or chronic effects. Therefore, the
concept of a “safe dose” for the non-cancer effects of TCE has been
applied here to a range of values (i.e., the multi-endpoint safety
range) which represents a “safe concentration” for multiple end-
points and multiple studies, with various degrees of conﬁdence in
study design, critical effect and POD, as illustrated by the shaded
cells in Table 1.
Speciﬁcally, the multi-endpoint safety range of the RfC for TCE
was determined by careful discernment of the conﬁdence, preci-
sion and safety associated with each endpoint-speciﬁc ﬂoor, in-
termediate and ceiling value. The ﬂoor of the multi-endpoint
uncertainty range of the RfC for TCE was determined by comparing
the candidate RfC values from each of the three studies (i.e., 2 mg/m3
for both the decreased thymus weight and controversial fetal car-
diac malformation endpoints, and 3 mg/m3 for the toxic nephrop-
athy endpoint). These three ﬂoor values are so closely clustered
that, based on the inherent precision, the values are toxicologically
indistinguishable. The endpoint-speciﬁc ﬂoor value of 3 mg/m3
based on toxic nephropathy represents the endpoint-speciﬁc ﬂoor
value of the highest overall conﬁdence from among the three
endpoint-speciﬁc ﬂoor values (see Table 1). Therefore, the value of
3 mg/m3 was selected to represent the ﬂoor value of the multi-
endpoint uncertainty range.
Similarly, the intermediate value of the multi-endpoint uncer-
tainty range of the RfC for TCE is determined by comparing the
endpoint-speciﬁc intermediate values from each of the three
studies (i.e., 20 mg/m3 for the decreased thymus weight endpoint,
10 mg/m3 for the controversial fetal cardiac malformation endpoint,
and 9 mg/m3 for the toxic nephropathy endpoint). The intermediate
values for the fetal cardiac malformation and toxic nephropathy
endpoints are so closely clustered that the values are toxicologically
indistinguishable. The endpoint-speciﬁc intermediate value of 9 mg/
m3 based on toxic nephropathy not only represents the endpoint-
speciﬁc intermediate value of the highest overall conﬁdence from
among the three endpoint-speciﬁc intermediate values (see
Table 1), but is lower than or equivalent to the other two endpoint-
speciﬁc intermediate values. Therefore, the endpoint-speciﬁc in-
termediate value of 9 mg/m3 was selected to represent the inter-
mediate value of the multi-endpoint uncertainty range.
The ceiling of the multi-endpoint uncertainty range of the RfC
for TCE is determined by comparing the endpoint-speciﬁc ceiling
values from each of the three studies (i.e., 63 mg/m3 for the
decreased thymus weight endpoint, 20 mg/m3 for the controversial
fetal cardiac malformation endpoint, and 30 mg/m3 for the toxic
nephropathy endpoint). The endpoint-speciﬁc ceiling values for the
fetal cardiac malformation and toxic nephropathy endpoints are
closely clustered, and the mathematical precision ranges of the two
values overlap8; the endpoint-speciﬁc ceiling value for decreased
thymus weight is substantially higher. Therefore, the endpoint-
speciﬁc ceiling value for toxic nephropathy (30 mg/m3) has been
selected here as the ceiling value for the multi-endpoint uncer-
tainty range, because it is the endpoint with higher degree of
conﬁdence than the controversial fetal cardiac malformations
endpoint.
In summary, the conﬁdence in each of the endpoint-speciﬁc
safety range was subsequently considered in the determination of
themulti-endpoint safety range for riskmanagement purposes (i.e.,
3 mg/m3 to 30 mg/m3). The higher-conﬁdence results of the NTP8 The mathematical precision (at HQ ¼ 1) associated with the endpoint-speciﬁc
ceiling value of 20 mg/m3 corresponds to a range of 19 mg/m3 to 30 mg/m3; the
mathematical precision (at HQ ¼ 1) of the endpoint-speciﬁc ceiling value of 30 mg/
m3 corresponds to a range of 28 mg/m3 to 45 mg/m3. Thus, the HQ ranges associated
with the implicit precision of each endpoint-speciﬁc ceiling value overlap.
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this safety range. The highly controversial results from the Johnson
et al. (2003) study, while associated with low conﬁdence (see
Supplemental materials, section 2), were nevertheless used to
support this safety range. This multi-endpoint safety range is
embedded within the individual safety range from Keil et al.
(2009); therefore, this study was also considered to be
conﬁrmatory.
3.3. Risk management use of “uncertainty spanning perhaps an
order of magnitude”
Toxicologists are not able to distinguish the absence of health
risk between any two or more values within the uncertainty range
determined for any RfD(C) by its inherent precision and safety. For
TCE speciﬁcally, toxicologists cannot differentiate the “safety” of
any value within a range of 3 mg/m3 to 30 mg/m3, nor can they
differentiate among hazard quotients (HQs) developed from any
valuewithin this range. Because of this, managers may use different
values within the multi-endpoint safety range, along with site-
speciﬁc exposure assessments, and other site risk management
considerations to make different decisions on a case-by-case basis.
Fig. 1 shows three hypothetical exposure scenarios overlaid on
the TCE safety range of 3 mg/m3 to 30 mg/m3. For example, when a
site-speciﬁc exposure assessment deﬁnes a range of exposures that
is primarily below the multi-endpoint safety range of 3 mg/m3 to
30 mg/m3, then the probability of inducing any non-cancer effects in
the exposure population is lower and the priority for any risk
management action is reduced (see Fig. 1a). In this case, a risk
manager may decide to take no action, or to delay action pending
further information. Such action would be readily seen as the cur-
rent practice at waste sites throughout the country.
In contrast, when the exposure assessment deﬁnes a range in
exposures that also exceeds the multi-endpoint safety range of
3 mg/m3 to 30 mg/m3, then the probability of inducing non-cancer
effects in the exposure population is higher and the priority for
risk management action is increased (see Fig. 1c). In this case, a risk
manager may decide to take action, or to ask for speciﬁc informa-
tion that would reﬁne the estimates of health risk and/or exposure.
Likewise, such action would be readily seen as the current practice
at waste sites throughout the country.
When the exposure assessment deﬁnes a range in exposures
that is primarily in the multi-endpoint safety range of 3 mg/m3 to
30 mg/m3, then risk managers can use the intermediate value in this
safety range, that is 9 mg/m3 and other site considerations, to gauge
whether a management action is needed or if further information
should be sought (see Fig. 1b).
4. Discussion
In this paper, a “safety range” is proposed for each RfD(C). This
safety range provides further clariﬁcation to the phrase “with un-
certainty spanning perhaps an order of magnitude” in the deﬁni-
tion of the RfD(C). This safety range can also be used with exposure
measurements at waste sites to develop a “hazard range”9 to
facilitate risk management decisions for non-cancer health effects.
This hazard range is similar in concept to the upper bound, excess,
lifetime, cancer risk range of 106 to 104.
The lower end of this safety range is the value of the RfD(C); the
lower end for the corresponding hazard range is a HQ value of 1.
These lower bounds are not only consistent with the deﬁnition and9 The term “hazard range” is introduced here since this incorporates the safety
range of the RfD(C) and also exposure measurements.intent of any RfD(C) value, but also reﬂect typical risk management
decisions about HQs at waste sites. The upper end of either of these
ranges can vary depending in part on the basis of choice of and
conﬁdence in the critical effect, the relevant POD and any of its
necessary adjustments, the aggregate uncertainty factor, and, for
the hazard range, the uncertainty inherent in the estimates of
exposure. For the safety ranges derived speciﬁcally for the three
TCE RfCs, the upper end varies from 10 to ~30 times above the
RfD(C). Fortunately, the information needed to determine the lower
and upper ends of these safety ranges are readily available for any
chemical on EPA’s IRIS or the International Toxicity Estimates for
Risk (ITER) on the National Library of Medicine’s Toxnet. The
resulting hazard ranges, expressed as the range of the HQ, can then
be determined from these safety ranges and available information
related to site-speciﬁc exposures.
Risk management decisions about exposure levels wholly below
the lower end of a safety range may be straightforward. For
example, when a site-speciﬁc exposure assessment deﬁnes TCE
exposures that are primarily below themulti-endpoint safety range
of 3 mg/m3 to 30 mg/m3, the risk manager may decide to take no
action, or to delay action pending further information. Risk man-
agement decisions may also be likewise straightforward when the
exposure levels are wholly above the upper end of this safety range
of 3 mg/m3 to 30 mg/; in such cases, a risk manager may decide to
take action, or to ask for speciﬁc information that would reﬁne the
estimates of health risk and/or exposure. Risk management de-
cisions about exposure levels wholly or partially within the range
are more complex; therefore, it may be helpful to have an inter-
mediate value within the safety range to aid in these decisions. The
intermediate values we develop are based on information that is
often available and reﬂects our best collective judgment. Other
criteria and judgments might also be reasonable. For example, a
recent publication notes ﬁve different ways to characterize the
uncertainty inherent in risk assessment values such as RfCs, with
the suggestion to develop a range being one of them (Beck et al.,
2016). In addition, the science panel of the ARA project “Beyond
Science and Decisions: From Problem Formulation to Dose
Response” recommended changes incorporating some of the
ﬁndings of Beck et al. (2016) into our proposed method.10 Some of
these suggestions have been adopted here.
Additionaldiscussion iswarrantedwith respect to establishing the
ﬂoor of our multi-endpoint safety range for TCE. The mathematical
precision of the cardiac or immune endpoint-speciﬁc ﬂoor value of
2 mg/m3 corresponds to a range of 1.5 mg/m3 to 2.5 mg/m3; the math-
ematicalprecisionof thenephropathyendpoint-speciﬁcﬂoor valueof
3 mg/m3 corresponds to a range of 2.5 mg/m3 to 3.5 mg/m3. Thus, the
ranges associated with the implicit precision of the three endpoint-
speciﬁc ﬂoors coincide at a precision of one signiﬁcant ﬁgure. Since
the endpoint-speciﬁc value of 3 mg/m3 based on toxic nephropathy
has the highest overall conﬁdence from among the three endpoint-
speciﬁc ﬂoor values (see Table 1), and since its precision coincides
with the other two endpoint-speciﬁc values, its choice of the ﬂoor of
the multi-endpoint range seems most reasonable.
Somediscussion is alsowarrantedwith respect to establishing the
ceiling value for this multi-endpoint safety range for TCE. For
example, the toxic nephropathy endpoint (30 mg/m3) is a preferred
representation of the ceiling value based on its overall conﬁdence,
whereas an alternative value of 20 mg/m3 based on cardiac effects is a
less plausible representation of the ceiling value, based on the high
uncertainty regarding the frankness and severity of the observed ef-
fect and the quantiﬁcation of the response, and the ongoing10 See http://allianceforrisk.org/wp-content/uploads/2015/07/DR8_Meeting_
Report_and_Appendices.pdf).
Fig. 1. Three Hypothetical Exposure Scenarios Overlaid on the TCE Safety Range. a. Hypothetical probability density function of exposures of TCE in indoor air lies primarily below
the 3 mg/m3 to 30 mg/m3 safety range. A relatively small proportion of exposures is higher than 3 mg/m3. Nominal actions or no further action may be warranted for risk man-
agement. b. Hypothetical probability density function of exposures of TCE in indoor air falling within the 3 mg/m3 to 30 mg/m3 safety range. A relatively small proportion of
exposures is higher than 9 mg/m3. Limited action may be warranted for risk management. c. Hypothetical probability density function of exposure of TCE in indoor air falling
within the 3 mg/m3 to 30 mg/m3 safety range. A relatively small proportion of exposures is higher than 30 mg/m3. Actions to reduce exposures may be warranted for risk
management.
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ment. Speciﬁcally, we favor the endpoint-speciﬁc ceiling value for
toxic nephropathy over the endpoint-speciﬁc ceiling value for fetal
cardiacmalformationon thebasis of higher conﬁdencenotonly in the
critical effect (high versus low) but also in the POD (medium versus
low); the latter comparison is of particular relevance since the POD
serves as the endpoint-speciﬁc ceiling value for each endpoint.
Nevertheless, themathematical precision ranges of theHQs based on
eitherof theendpoint-speciﬁc ceilingvaluesalsocoincide. In thiscase,
the values may be considered to be approximately equivalent,
enabling risk manager to conservatively account for potential devel-
opmental endpointswhen themulti-endpoint safety range is used as
the basis for risk management decisions.1111 Signiﬁcant science controversy surrounds the use of the Johnson et al. (2003)
study in regulating TCE exposures, and if the science community had a higher
level of conﬁdence in the Johnson et al. (2003) study, we would have used it to set
the ceiling of the range at 20 mg/m3, as opposed to 30 mg/m3. However, it is
important to recognize that the regulatory community, USEPA and States, are likely
to continue to support the use of this study, at least in the interim. Thus, risk
managers should consider whether to use 20 mg/m3 as the ceiling of the range
because it represents a POD, which can be, and has been (ATSDR, 2013a; 2103b),
interpreted as an “effects level”, or a level at which expression of the toxic effect is
often measurable or “real”. The risk of a toxic effect below these levels, especially in
acute or subchronic exposure, is minimal. Because of continued regulatory support
for the Johnson et al. study, at least over the interim, this may be an important
guidance issue for anyone making day to day risk based decisions for immediate
action.For TCE, the multi-endpoint safety range is based on ﬂoor, in-
termediate and ceiling values for effects of different exposure du-
rations (i.e., developmental or chronic exposure periods) with
expected different averaging times. Therefore, this range for TCE
can be applied to both long-term and short-term exposures, with
the associated differences in exposure averaging times. For shorter-
term exposures, the results from the Johnson et al. (2003) might
also be used to describe the best exposure averaging time, but if so,
this exposure averaging time should be based on the average time
of cardiac development in human fetal growth, approximately
20e25 days (based on Marcela et al., 2012; Hood, 2011;
Dhanantwari et al., 2009; Martin et al., 2002; Schleich, 2002),
rather than a speciﬁc window of time. This is because the use of
only a narrowwindow of exposure during the cardiac development
in humans would be inconsistent with the results of the Johnson
et al. (2003).12
It should be recognized that risk management decisions at12 Based on the available information, the human heart starts developing between
days 21 and 23 after gestation or later and may be completely formed by 43e46
days into gestation or later (Hood, 2011), indicating the length of cardiac devel-
opment in humans during fetal growth to be in the approximate range of 20e25
days. Since EPA’s RfC is based on all effects that occurred during the whole time of
cardiac development in the rat by Johnson et al. (2003), it is reasonable to use the
whole time of cardiac development in humans, 20e25 days, as the averaging time
for risk management decisions. This range falls within the previously stated range
of 21e30 days (see supplemental materials), and for similar reasons.
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with the same underlying hazard information, because other as-
pects of the site problem formulation differ. In fact, differences in
risk management decisions, and in the products of the individual
components of hazard characterization, doseeresponse assess-
ment, exposure assessment, and risk characterizations, should be
expected based on different problem formulations (Dourson et al.,
2013; Ethridge et al., 2015). Such differences in risk management
outcomes do not mean that the science behind the decision has
been tampered, but rather that these situations should be
addressed on a case-by-case basis.
As risk managers struggle with waste site decisions that inte-
grate various aspects of hazard identiﬁcation, dose response
assessment, exposure assessment and risk characterization, un-
derstanding the uncertainties underlying each component will
increasingly be important. Our approach is an attempt to put un-
certainties in perspective and advance transparency in the chemi-
cal risk assessment process. Such perspective and transparency
should promote more conﬁdent use of allowable levels, such as
RfDs and HQs, and their associated safety and hazard ranges, in
waste site management decision-making.
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